Claims
- 1. A compound of the tautomeric formula Ia, Ib or Ic ##STR19## or a physiologically tolerated salt of said compound wherein R has the following meaning:
- a radical of the formula V ##STR20## wherein one of R.sup.11 or R.sup.12 has the following meaning: ##STR21## wherein R.sup.14 and R.sup.15 together form a straight-chain or branched chain of 5 carbon atoms, and the other substituent R.sup.11 or R.sup.12 in each case means ##STR22## wherein R.sup.14 and R.sup.15 have the above-mentioned meaning, and R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are identical or different and independently of one another are
- 1) hydrogen,
- 2) (C.sub.1 -C.sub.5)-alkyl, straight-chain or branched, or
- 3) phenyl.
- 2. A compound of the formula Ia, Ib or Ic as claimed in claim 1, or a physiologically tolerated salt of said compound, wherein R has the following meaning:
- a radical of the formula V wherein R.sup.11 has the following meaning ##STR23## wherein R.sup.12 has the following meaning: ##STR24## R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are identical or different and independently of one another are
- 1) hydrogen or
- 2) (C.sub.1 -C.sub.5)-alkyl, straight-chain or branched.
- 3. A compound of the formula Ia, Ib or Ic as claimed in claim 1 or physiologically tolerated salt of said compound wherein R.sup.11 has the following meaning: ##STR25## wherein R.sup.14 and R.sup.15 together form a (C.sub.5)-alkyl chain, and R.sup.5, R.sup.6, R.sup.7, R.sup.8, are identical or different and independently of one another are
- 1) hydrogen or
- 2) (C.sub.1 -C.sub.4)-alkyl straight chain or branched.
- 4. 2-[(3-Methyl-sulfonyl-4-piperidylbenzoyl)(aminoiminomethyl) -amino]ethane-1,1-bisphosphonic acid, or tetraethyl 2-[(3-methylsulfonyl-4-piperidylbenzoyl)(aminoiminomethyl)-amino ]ethane-1,1-bisphosphonate.
- 5. A pharmaceutical containing an effective amount of at least one of the compounds of the tautomeric formula Ia, Ib or Ic as claimed in claim 1 or at least one of the physiologically tolerated salts of said compounds, in addition to at least one pharmaceutically acceptable and physiologically tolerated ancillary substance or excipient or diluent.
- 6. A method for the treatment of degenerative disorders of the bone system, wherein said method comprises administering an effective amount of a pharmaceutical composition of claim 1, wherein said degenerative disorder of the bone system is Paget's disease, metastatic osteocarcinoma, hypercalcemia or osteoporosis.
Priority Claims (3)
Number |
Date |
Country |
Kind |
42 40 422.3 |
Dec 1992 |
DEX |
|
43 16 019.0 |
May 1993 |
DEX |
|
43 32 362.6 |
Sep 1993 |
DEX |
|
Parent Case Info
This is a division of application Ser. No. 08/159,119, filed Nov. 30, 1993, now U.S. Pat. No. 5,395,826.
US Referenced Citations (5)
Foreign Referenced Citations (7)
Number |
Date |
Country |
2085171 |
Jun 1993 |
CAX |
0010147A1 |
Apr 1980 |
EPX |
0186405A3 |
Jul 1986 |
EPX |
0252504A1 |
Jan 1988 |
EPX |
0298553A1 |
Jan 1989 |
EPX |
0416499A2 |
Mar 1991 |
EPX |
0546548A1 |
Jun 1993 |
EPX |
Non-Patent Literature Citations (3)
Entry |
Abstract of Isomura et al., Heterocycle-Substituted Bis(phosphonic acid Derivatives and Bone Absorption Inhibitors Containing Them, Chemical Abstracts, 113(9):812, 78695b (1990). |
"New Methods of Preparative Organic Chemistry IV, Synthesis Using Heterocyclic Amides (Azolides)", Staab, H. A., Angew. Chem. Internat. Edit. 1(7):351-367 (1962). |
Advanced Organic Chemistry-Reactions, Mechanisms, and Structure March J., Fourth Edition, pp. 348-352 (1983). |
Divisions (1)
|
Number |
Date |
Country |
Parent |
159119 |
Nov 1993 |
|